CHU UCL Namur

At CHU UCL Namur, investigators are assessing innovative preventive strategies to lower the incidence of heart attacks and strokes in high‑risk patients, with a focus on the novel agent inclisiran.

• Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• Evaluation of major adverse cardiovascular events
• Risk‑reduction therapies in primary prevention

The goal is to provide safer, more effective options for long‑term cardiovascular health and to reduce the burden of disease in the community.

The oncology department runs multiple studies aimed at improving outcomes for malignant blood‑forming and lymphatic disorders, including trials of the bispecific antibody odronextamab.

• B‑Cell Non‑Hodgkin’s Lymphoma
• Follicular lymphoma
• Classical Hodgkin Lymphoma
• Relapsed or refractory lymphomas

By comparing new immunotherapies with standard chemotherapy, these studies seek to extend survival and enhance quality of life for patients with challenging lymphoid cancers.

A comprehensive cancer program at CHU UCL Namur explores advanced treatments for solid tumors, featuring the selective estrogen receptor degrader camizestrant and the checkpoint inhibitor pembrolizumab.

• ER+/HER2‑ negative early breast cancer
• Muscle‑invasive bladder cancer
• Other solid tumor investigations

The trials aim to reduce disease recurrence, improve surgical outcomes, and offer new therapeutic options for patients with early‑stage and locally advanced cancers.